Adults 0 to 71, any sex, with Hemorrhagic Fever, Ebola. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Cohorts 1 and 3: Number of Participants With Serious Adverse Events (SAEs)Primary· Up to 60 months
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.
Group
Value
95% CI
Cohort 1: Ad26.ZEBOV + MVA-BN-Filo
49
Cohort 1: Placebo
1
Cohort 3: Ad26.ZEBOV + MVA-BN-Filo
2
Cohort 3: Placebo
1
Adverse events — posted to ClinicalTrials.gov
Time frame: Cohorts 1 and 3: Up to 60 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of the study is to assess the long-term safety profile of Ad26.ZEBOV and MVA-BN-Filo in participants previously exposed to these vaccines in Phase 1, 2, or 3 clinical studies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05064956 — Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)
· Phase 2
· completed
NCT04556526 — A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women
· Phase 3
· completed
NCT04228783 — A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
· Phase 3
· completed
NCT03929757 — A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
· Phase 2
· completed
NCT02876328 — Partnership for Research on Ebola VACcinations
· Phase 2
· completed
Other Janssen Vaccines & Prevention B.V. trials
Trials by the same sponsor.
NCT05901636 — A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults
· Phase 1, PHASE2
· completed
NCT05327816 — A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Year
· Phase 1, PHASE2
· terminated
NCT05091307 — A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
· Phase 3
· completed
NCT05101486 — A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years
· Phase 3
· completed
NCT05083585 — A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Ag
· Phase 3
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Vaccines & Prevention B.V.
Last refreshed: 2 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02661464.